On Thursday, September 23rd RESIST-TB hosted this webinar webinar featuring Dr. Keertan Dheda, who will present the results of the recently-completed NeXT clinical trial for MDR-TB. This study evaluated the impact of a new injection-free six-to-nine month treatment regimen of linezolid, bedaquiline, levofloxacin, pyrazinamide (PZA) and ethionamide/high dose isoniazid (INH) compared to the conventional empiric injection-based regimen. Read more here.
top of page
Recent Posts
See AllThis week, the WHO recommended four new treatments for patients with MDR-TB. Three of the regimens were from the End TB trial, and one...
130
The Health Justice Initiative in South Africa has reported that the South African government is utilizing the Competition Act to...
290
Johnson and Johnson successfully applied for a patent extension on bedaquiline; however, in a big win for LMI countries, the company has...
200
bottom of page
Comments